FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

N.J.S.A. 45:14-73 and N.J.A.C. 13:39-4.20(a)-(b) require any pharmacy located in another state to register with the Board of Pharmacy if it ships, mails, distributes or delivers legend drugs, devices or controlled dangerous substances into New Jersey under a prescription. Shipping without registration is unlawful. The application must include the pharmacist-in-charge's name and home-state license number (a New Jersey license is not required). It must also include a dated copy of the most recent inspection report from an inspection within the past two years by the home-state regulatory or licensing agency, and a letter of good standing. Registration renews every year. Registrants must keep their home-state license, notify the Board of closure or disciplinary action, and provide a toll-free telephone line to a pharmacist during regular hours. N.J.A.C. 13:39-4.20 has no separate nonresident sterile-compounding permit.

The lead citation N.J.S.A. 45:14-80 is wrong: that section covers pharmacy technicians. The out-of-state pharmacy statute is N.J.S.A. 45:14-73, which N.J.A.C. 13:39-4.20 cites. The rule was last amended by 49 N.J.R. 3761(a), effective 2017-12-04, and was still current on Cornell on 2026-09-23. The Board's website (njconsumeraffairs.gov) blocked automated access with bot protection, so its current application forms were not checked. Registration covers shipments made under a prescription. Office-use (non-patient-specific) compounding for human use is separately restricted; see office_use_503a. No 2025-2026 rule changes on nonresident registration were found, but the search budget was limited.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

N.J.A.C. 13:39-11.18 (sterile) and 13:39-11A.6 (non-sterile) say that, without a valid patient-specific prescription or medication order, pharmacists and pharmacy staff 'shall not prepare' compounded preparations for human use for a licensed prescriber to use in their practice, 'except to the extent permitted by Federal law.' Both rules allow compounding for a prescriber's non-human (veterinary) practice use without a prescription. FDA reads section 503A as requiring patient-specific prescriptions, so in practice office stock for human use has to come from an FDA-registered 503B outsourcing facility. The NJ Board of Pharmacy enforces these rules.

Both rules were last amended by 49 N.J.R. 3761(a), effective 2017-12-04, and were shown as current on Cornell on 2026-09-23. The 'except to the extent permitted by Federal law' clause ties New Jersey's rule to the federal position. If federal law or FDA policy changed, the state answer could change without a state rulemaking.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

The NJ Department of Health's Drug and Medical Device Registration page says 'New Jersey law requires any business that distributes prescription or non-prescription drugs or medical devices to register with the Department of Health.' Its fee schedule covers locations in or out of state. The Department's FAQ says outsourcing facilities registered under section 503B 'may apply for a wholesale drug/medical device registration.' It also says an applicant may not conduct wholesale drug business in the state until a registration is issued. Under N.J.A.C. 8:21-3A, 'wholesale distributor' includes manufacturers, and 'manufacturer' includes anyone who compounds a drug. N.J.A.C. 8:21-3A.4 lets the Department accept an out-of-state distributor's comparable home-state license through reciprocity. No outsourcing-facility permit appears in the NJ Board of Pharmacy rules (N.J.A.C. 13:39). A 503B that also dispenses patient-specific prescriptions into NJ as a pharmacy would face the out-of-state pharmacy registration rule (N.J.A.C. 13:39-4.20).

The Department's FAQ says 503B facilities 'may apply' for the wholesale registration rather than saying they must. The general registration requirement and the rule that no wholesale business may be conducted before registration support 'yes.' N.J.A.C. 8:21-3A was last substantively amended in 2006 (R.2006 d.391), which is possibly stale, though the Department pages are dated 2026. No FDA-inspection or in-state representative requirement for 503Bs was found. The NJ Board of Pharmacy site blocked automated access.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; New Jersey is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

N.J.S.A. 24:21-10 requires every person who dispenses controlled dangerous substances in New Jersey to obtain a registration from the Division of Consumer Affairs, with a separate registration at each principal place of business or professional practice. N.J.A.C. 13:45H-1.2(c) applies this to every person who dispenses, 'including prescribing, administering, compounding, or delivering', and requires renewal every year; 13:45H-1.2(f) requires a separate application and registration for each place of business or professional practice. N.J.A.C. 13:45H-1.1 sets an annual fee of $40 for dispensers, charged per place of practice. The rule is not limited to physicians, so APNs and PAs who prescribe CDS are also covered.

Source older than 2 years - possibly stale: the rule text we could open is the Division's copy last revised 2019-02-19 (fee may have changed). The Drug Control Unit's own pages (njconsumeraffairs.gov/dcu) blocked automated access, so the application form and the order relative to DEA could not be confirmed; the sources opened do not state whether the NJ registration must come before DEA. Check with the NJ Drug Control Unit: https://www.njconsumeraffairs.gov/dcu/.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

N.J.A.C. 13:45A-35.9 (implementing N.J.S.A. 45:1-46.1) requires practitioners to access the NJPMP the first time they prescribe a Schedule II drug or any opioid for acute or chronic pain, the first time they prescribe a Schedule III or IV benzodiazepine, each time a Schedule II drug is prescribed for pain in a hospital emergency department, and quarterly while a patient continues on a Schedule II drug, opioid or benzodiazepine. For other Schedule III or IV drugs (which would include testosterone), a look-up is required only when the practitioner has a reasonable belief the person is seeking the drug for misuse, abuse or diversion. Exceptions include veterinarians, direct administration, prescriptions filled by an institutional pharmacy, hospice patients, emergency-department supplies of 5 days or less, system outages and waivers, and post-operative/acute-trauma prescriptions under a 30-day supply (statute). The Division of Consumer Affairs runs the NJPMP and violations are professional misconduct.

Source older than 2 years - possibly stale. The rule was adopted 48 N.J.R. 2374(a) eff. 11/7/2016 and amended 51 N.J.R. 624(a) eff. 5/6/2019 (per LII history note). The statute as enacted in 2015 (P.L.2015, c.74) covered only Schedule II for pain; later amendments added opioids and benzodiazepines - the current consolidated statute text could not be opened (NJ Division of Consumer Affairs site blocked automated access), so the rule text was relied on. NJ PMP page: https://www.njconsumeraffairs.gov/pmp/Pages/default.aspx.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

N.J.A.C. 13:35-7.5 (under N.J.S.A. 45:9-22.11) says a physician dispensing drugs for a fee may not dispense more than a seven-day supply of a drug or its equivalent, nor dispense it more often than once every 30 days, and may charge no more than actual acquisition cost plus 10 percent. The patient must be told the drug is available outside the office. The fee and supply limits do not apply to practices 10 or more miles from a pharmacy, oncology or AIDS protocols, topical medications, certain health-care settings and nutritional supplements.

Last amended October 15, 2018 (50 N.J.R. 2153(a)); source older than 2 years but current at access. New Jersey CDS registration also required for controlled substances.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) Telehealth providers must hold a New Jersey license and remain subject to New Jersey boards; an out-of-state provider who only consults with a New Jersey licensee and does not direct care is exempt. Separately, a telemedicine or telehealth organization (as defined in N.J.S.A. 45:1-61) must register with the Department of Health before providing services and renew annually ($1,500 nonrefundable registration fee) (N.J.A.C. 8:53-2.1). (2) No general in-person exam is required: licensees must identify the patient, review history and records first, and use real-time two-way video unless they determine audio plus store-and-forward meets the standard of care; prescriptions may not rest solely on an online questionnaire. (3) Schedule II prescriptions require an initial in-person exam and in-person visits at least every three months (exception for stimulants for minors with audio-video and parental consent); Schedule III drugs such as testosterone have no New Jersey-specific telehealth limit. (4) IMLC: member.

Classified conditional because of the Department of Health registration requirement for telemedicine/telehealth organizations (N.J.S.A. 45:1-64; N.J.A.C. 8:53). Whether a given practice is a 'telemedicine or telehealth organization' turns on the statutory definition in N.J.S.A. 45:1-61 (not fetched directly). Board rules 13:35-6B date from 2020 and remain the current text; the statute (45:1-62) sets the same Schedule II in-person rule. Source older than 2 years - possibly stale (rules dated 2020/2021, but shown as current text on 2026-09-23).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

N.J.A.C. 13:35-6.4 lets physicians delegate intradermal, intramuscular or subcutaneous injections (excluding local anesthetics, controlled substances, allergenic testing/treatment, non-FDA-approved drugs and chemotherapy) to certified medical assistants, with the physician remaining on the premises and near the treatment room. No Board of Nursing or Board of Medical Examiners statement on RN administration of neuromodulators or dermal fillers was located; the NJ Division of Consumer Affairs board pages blocked automated access on 2026-09-23.

Check with the NJ Board of Nursing (njconsumeraffairs.gov/nur). Whether cosmetic fillers (intradermal/subdermal) fall within the CMA rule was not confirmed.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

A December 2025 review by Post & Schell reports that in New Jersey IV therapy in med spas may be administered by physicians, RNs and PAs, and by LPNs with specialized IV certification recognized by the Board of Nursing, while medical assistants are prohibited. This matches the medical board's CMA rule, which permits CMAs to give only intradermal, intramuscular and subcutaneous injections. No New Jersey board statement on elective IV hydration (such as individual-exam or standing-order limits) was located.

Standing-order and prior-exam rules for elective IVs in New Jersey were not confirmed.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

N.J.A.C. 13:35-6.16 permits solo practice, partnerships, professional associations/LLCs and professional corporations composed solely of licensed health care professionals. Physicians may be employees of a general business corporation only in specified settings, for example where the corporation is licensed by the Department of Health as an HMO, hospital, long- or short-term care facility or ambulatory care facility, or in workplace clinics, educational institutions and similar settings. A lay-owned med spa therefore generally cannot employ physicians unless it holds a qualifying health facility licence. Permit Health also rates New Jersey strict (Allstate v. Northfield Medical, 2017).

Rule last amended 2011 (possibly stale in wording) but in force per LII on 2026-09-23.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

N.J.A.C. 13:35-4A.3 defines surgery as a manual or operative procedure, including the use of lasers, performed on the body. Physicians may authorize advanced practice clinicians (APNs, PAs) to perform minor procedures consistent with their scope and collaborative agreements (13:35-4A.19). The electrologist rules (13:35-12) do not mention lasers, and no rule letting RNs, estheticians or laser technicians perform laser hair removal was located. Secondary guides also describe New Jersey as treating laser procedures as surgery limited to physicians.

The 'no' rests on the surgery definition plus the absence of a delegation rule; no Board statement expressly addressing laser hair removal by RNs was located. Confirm with the Board of Medical Examiners.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

The NJ Department of Health's Clinical Laboratory Improvement Service runs a Clinical Laboratory Licensing Program that 'provides New Jersey State licensure to collection stations and clinical laboratories performing patient specimen collection and testing', in addition to acting as the CLIA agency. Labs licensed in New Jersey must also meet demographic-data reporting requirements (N.J.S.A. 45:9-42.45 to -42.49).

Out-of-state coverage not confirmed; ask NJDOH CLIS (CLIS@doh.nj.gov / CLIAlab@doh.nj.gov). The underlying licensing statute was not fetched in this pass.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm New Jersey's rule. New Jersey's lab regulator (CLIA state agency) is New Jersey Dept. of Health, Clinical Laboratory Improvement Service (CLIAlab@doh.nj.gov, 609-718-8072). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) lists New Jersey among states that restrict independent test ordering; not confirmed against state law. New Jersey licenses labs (see lab licensing). The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. New Jersey is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

S1042/A1421, signed Jan 12, 2026, prohibits selling, offering for sale or distributing cosmetics with intentionally added PFAS. A 2026 compliance compilation gives the effective date as Jan 12, 2028. New Jersey is also listed among the states banning the sale of cosmetics tested on animals.

The PFAS effective date is from one compilation (Adherent); confirm with NJDEP or the NJ Division of Consumer Affairs. The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.